No adverse impact on serum lipids of the irreversible aromatase inactivator aromasin (R) (Exemestane (E)) in first line treatment of metastatic breast cancer (MBC) : companion study to a European Organization of Research and Treatment of Cancer (Breast Group) Trial with Pharmacia and Upjohn

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報

  • CRID
    1570009750057809536
  • NII論文ID
    10011164258
  • データソース種別
    • CiNii Articles

問題の指摘

ページトップへ